Appointment dossier — Bladder Cancer
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Bladder Cancer
- Genistein — Review evidence · 1 positive · PMID 42133114
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT07097142 · Phase 3 — Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study (United States)
- NCT04574960 · Phase 3 — Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL) (Canada)
- NCT06929286 · Phase 3 — A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC) (United States)
- NCT07566156 · Phase 3 — Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309) (United States)
- NCT06241755 · Phase 3 — Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC) (China)
- NCT03844256 · Phase 1 / Phase 2 — A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study (Netherlands)
- NCT07646145 · Phase 2 — Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer (China)
- NCT06682728 · Phase 2 — Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence (United States)
- NCT05710848 · Phase 1 / Phase 2 — A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer (United States)
- NCT06351904 · Phase 1 — A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy (Australia)
- NCT06778863 · Phase 1 — A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation (United States)
- NCT07090499 · Phase 1 — A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors (United States)
- NCT06173349 · Phase 1 — PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer (United States)
- NCT04970472 — Bio Clinical Collection of Urothelial Carcinoma (France)
- NCT06537960 — Interest of Late Images for the Assessment of Extensions in 18FGD PET-CT of Muscle-Invasive Bladder Cancers (France)
- NCT05792722 — Evaluating Safety and Efficacy of Prostate-sparing Radical Cystectomy (United States)
- NCT05646485 — Bladder Cancer Screening Trial (United States)
- NCT06026189 — Safely Reduce Cystoscopic Evaluations for Hematuria Patients (Netherlands)
Most-relevant first: trials that name Bladder Cancer, then broader trials you may still qualify for. 397 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.
Questions to ask your oncologist
- Of the open trials I found (for example NCT07097142), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?
- Should my tumor tissue be stored (biobanked) for future testing or trials?